JasmineZainMD

Hematology • Duarte, CA

Hematologic Oncology

Professor Department of Hematology and Hemoatopoeitic stem cell transplantation Director T cell Lymphoma program

Join to view full profile

Dr. Zain is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Zain's full profile

Already have an account?

Office
1500 Duarte Rd
Duarte, CA 91010
Phone+1 626-256-4673

Education & Training

NYU Grossman School of MedicineFellowship, Hematology and Medical Oncology, 1996 - 1999
NYU Grossman School of MedicineFellowship, Hematology and Medical Oncology, 1995 - 1997
NYU Grossman School of MedicineFellowship, Hematology and Medical Oncology, 1994 - 1995
Zucker School of Medicine at Hofstra/Northwell at Forest Hills HospitalResidency, Internal Medicine, 1989 - 1992
Fatima Jinnah Medical CollegeClass of 1987

Certifications & Licensure

CA State Medical License 2002 - 2025
NY State Medical License 1994 - 2025
CT State Medical License 2001 - 2003
NC State Medical License 1992 - 2001
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Clinical Trials

Safety and Efficacy Study of a BTK Inhibitor in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma Start of enrollment: 2011 May 01
Completed
Phase 2
Phase 1 Dose Finding Study of Belinostat for Treatment of Patients With Peripheral T-cell Lymphoma (PTCL) Start of enrollment: 2013 May 01
Completed
Phase 1
Brentuximab Vedotin and Lenalidomide in Treating Patients With Relapsed or Refractory T-Cell Lymphomas Start of enrollment: 2019 Mar 01
Withdrawn
Phase 1
Venetoclax and Romidepsin in Treating Patients With Recurrent or Refractory Mature T-Cell Lymphoma Start of enrollment: 2018 Aug 21
Completed
Phase 2
Nivolumab With Standard of Care Chemotherapy for Peripheral T Cell Lymphomas Start of enrollment: 2018 Nov 07
Active, not recruiting
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

1 citations
Valemetostat for patients with relapsed or refractory peripheral T-cell lymphoma (VALENTINE-PTCL01): a multicentre, open-label, single-arm, phase 2 study.
Pier Luigi Zinzani, Koji Izutsu, Neha Mehta-Shah, Stefan K Barta, Kenji Ishitsuka
The Lancet. Oncology. 2024-12-01
1 citations
Valemetostat monotherapy in patients with relapsed or refractory non-Hodgkin lymphoma: a first-in-human, multicentre, open-label, single-arm, phase 1 study.
Dai Maruyama, Eric Jacobsen, Pierluigi Porcu, Pamela Allen, Kenji Ishitsuka
The Lancet. Oncology. 2024-12-01
Safety and activity of CTX130, a CD70-targeted allogeneic CRISPR-Cas9-engineered CAR T-cell therapy, in patients with relapsed or refractory T-cell malignancies (COBAL...
Swaminathan P Iyer, R Alejandro Sica, P Joy Ho, Anca Prica, Jasmine Zain
The Lancet. Oncology. 2024-11-28

Abstracts/Posters

Long Term Outcomes of Patients with Aggressive T-Cell Non-Hodgkin Lymphoma Undergoing Allogeneic Stem Cell Transplantation: Retrospective Results from a Single Center
Jasmine M. Zain, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Blinatumomab/Lenalidomide in Relapsed/Refractory Non-HodgkinÍs Lymphoma: A Phase I California Cancer Consortium Study of Safety, Efficacy and Immune Correlative Analysis
Jasmine Zain, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Phase 1 Results of Anti-PD-Ligand 1 (Durvalumab) & Lenalidomide in Patients with Cutaneous T Cell Lymphoma and Correlation with Programmed Death Ligand 1 Expression an...
Jasmine Zain, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Preliminary Results from a Phase 2 Trial of Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (CHEP-BV) Followed By BV Consolidation in...
Jasmine Zain, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Final Results of Phase 1/1b Study of Tenalisib, Dual PI3K _/_ Inhibitor in Patients with Relapsed/Refractory T-Cell Lymphoma
Jasmine Zain, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Pembrolizumab and Copanlisib for the Treatment of Relapsed or Refractory Mature T-Cell Lymphomas
Jasmine Zain, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Dose Optimization of Duvelisib in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma from the Phase 2 Primo Trial: Selection of Regimen for the Dose-Expan...
Jasmine Zain, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Join now to see all

Lectures

Preliminary Results of the Stapled Peptide ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Two Phase IIa Dose Expansion Cohorts in Relapsed/Refractory TP53 Wild-Type ...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Pembrolizumab in Patients with Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL): Data from the Keynote-013 and Keynote-170 StudiesClinically Re...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
6th Annual Conference On How The Experts Treat Hematologic Malignancies
City of Hope, Santa Monica, California - 9/18/2013

Press Mentions

City of Hope Doctors and Scientists Present Research on Novel Cancer Therapies at American Society of Hematology (ASH) Annual ConferenceDecember 10th, 2024
City of Hope Doctors Present Research on First KRAS Inhibitor and CAR T Cell Therapy at ASCOMay 29th, 2019
City of Hope Clinical and Laboratory Investigators Present New Research at the 60December 4th, 2018

Committees

Co-Chair, CPRMC (Cancer Protocol Regulatory and Monitoring Committee), City of Hope National Medical Center 2017 - Present
Member, CPRMC (Cancer Protocol Regulatory and Monitoring Committee), City of Hope National Medical Center 2016 - 2017